Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.
Start 7-day free trial → Log in

PL8177

Other · developed by Palatin Technologies

Phase 2 Most advanced trial
PTN Developer
1 Registered trials

What is PL8177?

PL8177 is an investigational drug studied in Ulcerative Colitis, Ulcerative Colitis Acute, Ulcerative.

At a glance

Also known as
Active study medication
Drug type
Other
Therapy area
Gastroenterology
Developer
Palatin Technologies, Inc (PTN)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 2
UNII
16134B0YTH

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT05466890 Phase 2 Ulcerative Colitis Active not recruiting PTN

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

UlcerativeUlcerative ColitisUlcerative Colitis AcuteUlcerative Colitis Flare

More from Palatin Technologies

PL-3994 Phase 2 PL9643 Phase 3

Sources

Updated Oct 3, 2026. Something wrong or missing? Report it on the PTN page.

Follow PTN, the company behind PL8177

See PTN's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

PTN catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.